Format

Send to

Choose Destination
Cancer Lett. 2014 May 1;346(2):188-96. doi: 10.1016/j.canlet.2014.01.006. Epub 2014 Jan 22.

Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia.

Author information

1
INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Equipe 4: Inflammation, Cancer, Cancer Stem Cells, Nice F-06204, France; Université de Nice Sophia-Antipolis, Faculté de Médecine, Nice F-06107, France.
2
Harvard School of Public Health, Department of Genetics and Complex Diseases, Boston, MA 02115, USA.
3
INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Equipe 7: Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice F-06204, France; Université de Nice Sophia-Antipolis, Faculté de Médecine, Nice F-06107, France.
4
INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Equipe 4: Inflammation, Cancer, Cancer Stem Cells, Nice F-06204, France; Université de Nice Sophia-Antipolis, Faculté de Médecine, Nice F-06107, France; Centre Hospitalier Universitaire de Nice, Service d'Oncologie Pédiatrique, Hôpital de l'Archet, Nice, France. Electronic address: peyron@unice.fr.

Abstract

There is a global and urgent need for expanding our current therapeutical arsenal against leukemia in order to improve their actual cure rates and fight relapse. Targeting the reprogrammed, altered cancer metabolism is an emerging strategy which should profoundly affect cancer cells in their intimate and irrepressible needs and addictions for nutrients uptake and incorporation into the biomass during malignant proliferation. We present here how metformin, an anti-diabetic drug that has attracted a strong interest for its recently discovered anti-cancer properties, can be envisioned as a new adjuvant approach to treat leukemia. Metformin may have a double-edged sword effect (i) by acting on the organism to decrease hyperglycaemia and hyperinsulinemia in diabetic patients and (ii) at the cellular level, by inhibiting the mTORC1-cancer supporting pathway through AMPK-dependent and independent mechanisms.

KEYWORDS:

AMPK; Acute leukemia; Adjuvant chemotherapy; Metformin; mTOR

PMID:
24462823
DOI:
10.1016/j.canlet.2014.01.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center